abcam

Product datasheet

Human CDK4 knockout HeLa cell line ab255378

4 Images

Overview

Product name	Human CDK4 knockout HeLa cell line
Parental Cell Line	HeLa
Organism	Human
Mutation description	Knockout achieved by using CRISPR/Cas9, 139 bp insertion in exon 2 and 2 bp deletion in exon 2
Passage number	<20
Knockout validation	Sanger Sequencing, Western Blot (WB)
Tested applications	**Suitable for:** WB
Biosafety level	2
General notes	**Recommended control:** Human wild-type HeLa cell line (**ab255928**). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1. **Cryopreservation cell medium:** Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose. **Culture medium:** DMEM (High Glucose) + 10% FBS **Initial handling guidelines:** Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability. 1. Thaw the vial in 37°C water bath for approximately 1-2 minutes. 2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution. 3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method. Based on cell count, seed cells in an appropriate cell culture flask at a density of $2x10^4$ cells/cm^2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. 4. Incubate the culture at 37°C incubator with 5% CO_2. Cultures should be monitored daily. **Subculture guidelines:** All seeding densities should be based on cell counts gained by established methods. A guide seeding density of $2x10^4$ cells/cm^2 is recommended. A partial media change 24 hours prior to subculture may be helpful to encourage growth, if

required.
Cells should be passaged when they have achieved 80-90% confluence.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our **limited use license** and **patent pages**.

We will provide viable cells that proliferate on revival.

Properties

Number of cells	1 x 10^6 cells/vial, 1 mL
Adherent /Suspension	Adherent
Tissue	Cervix
Cell type	epithelial
Disease	Adenocarcinoma
Gender	Female
STR Analysis	Amelogenin X D5S818: 11, 12 D13S317: 12, 13.3 D7S820: 8, 12 D16S539: 9, 10 vWA: 16, 18 TH01: 7 TPOX: 8,12 CSF1PO: 9, 10
Mycoplasma free	Yes
Storage instructions	Shipped on Dry Ice. Store in liquid nitrogen.
Storage buffer	Constituents: 8.7% Dimethylsulfoxide, 2% Cellulose, methyl ether

Target

Function	Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a cell-cycle-dependent manner and represses its transcriptional activity. Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex.
Involvement in disease	Defects in CDK4 are a cause of susceptibility to cutaneous malignant melanoma type 3 (CMM3) [MIM:609048]. Malignant melanoma is a malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites.
Sequence similarities	Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. CDC2/CDKX subfamily. Contains 1 protein kinase domain.
Post-translational modifications	Phosphorylation at Thr-172 is required for enzymatic activity. Phosphorylated, in vitro, at this site by CCNH-CDK7, but, in vivo, appears to be phosphorylated by a proline-directed kinase. In the cyclin D-CDK4-CDKN1B complex, this phosphorylation and consequent CDK4 enzyme activity, is dependent on the tyrosine phosphorylation state of CDKN1B. Thus, in proliferating cells, CDK4 within the complex is phosphorylated on Thr-172 in the T-loop. In resting cells, phosphorylation on Thr-172 is prevented by the non-tyrosine-phosphorylated form of CDKN1B.

Cellular localization	Cytoplasm. Nucleus. Membrane. Cytoplasmic when non-complexed. Forms a cyclin D-CDK4 complex in the cytoplasm as cells progress through G(1) phase. The complex accumulates on the nuclear membrane and enters the nucleus on transition from G(1) to S phase. Also present in nucleoli and heterochromatin lumps. Colocalizes with RB1 after release into the nucleus.

Applications

The Abpromise guarantee Our **Abpromise guarantee** covers the use of ab255378 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application	Abreviews	Notes
WB		Use at an assay dependent concentration. Predicted molecular weight: 34 kDa.

Images



Western blot - Human CDK4 knockout HeLa cell line (ab255378)

All lanes : Anti-Cdk4 antibody [EPR17525] (**ab199728**) at 1/2000 dilution

Lane 1 : Wild-type HeLa cell lysate
Lane 2 : CDK4 knockout HeLa cell lysate

Lysates/proteins at 20 µg per lane.

Performed under reducing conditions.

Predicted band size: 34 kDa
Observed band size: 34 kDa

Lanes 1- 2: Merged signal (red and green). Green - **ab199728** observed at 34 kDa. Red - Anti-Vinculin antibody [VIN-54] observed at 124 kDa.

ab199728 was shown to react with CDK4 in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line ab255378 (knockout cell lysate **ab263780**) was used. Wild-type HeLa and CDK4 knockout HeLa cell lysates were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. **ab199728** and Anti-Vinculin antibody [VIN-54] overnight at 4°C at a 1 in 2000 dilution and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW)

preadsorbed (**ab216773**) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (**ab216776**) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.



Western blot - Human CDK4 knockout HeLa cell line (ab255378)

All lanes : Anti-Cdk4 antibody [EPR4513-32-7] (**ab108357**) at 1/1000 dilution

Lane 1 : Wild-type HeLa cell lysate
Lane 2 : CDK4 knockout HeLa cell lysate

Lysates/proteins at 20 µg per lane.

Performed under reducing conditions.

Predicted band size: 34 kDa
Observed band size: 34 kDa

Lanes 1- 2: Merged signal (red and green). Green - **ab108357** observed at 34 kDa. Red - Anti-Vinculin antibody [VIN-54] observed at 124 kDa.

ab108357 was shown to react with CDK4 in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line ab255378 (knockout cell lysate **ab263780**) was used. Wild-type HeLa and CDK4 knockout HeLa cell lysates were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. **ab108357** and Anti-Vinculin antibody [VIN-54] overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (**ab216773**) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (**ab216776**) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.



Sanger Sequencing - Human CDK4 knockout HeLa cell line (ab255378)

Allele-1: 2 bp deletion in exon 2.

Sanger Sequencing - Human CDK4 knockout HeLa cell line (ab255378)

Allele-2: 139 bp insertion in exon 2.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit **https://www.abcam.com/abpromise** or contact our technical team.

Terms and conditions

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors